<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114476</url>
  </required_header>
  <id_info>
    <org_study_id>GDM-Imp</org_study_id>
    <nct_id>NCT02114476</nct_id>
  </id_info>
  <brief_title>Effect of Implantable Contraception on Type-2 DM and Metabolic Syndrome in Women With History of Gestational DM</brief_title>
  <official_title>Effect of Implantable Progestin-only Contraception on the Incidence of Type 2 Diabetes and Metabolic Syndrome in Thai Women With History of Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of implantable contraception on the
      incidence of diabetes mellitus in women with history of gestational diabetes mellitus
      comparing with those using nonhormonal contraceptives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes mellitus (GDM) was defined as abnormal glucose tolerance detected for
      the first time in pregnancy. GDM is a well-known risk factor for developing overt diabetes
      later in life, especially type 2 diabetes. About 50-60% of woman with prior GDM will develop
      type 2 diabetes during their lifetime. Recent studies show that women with previous GDM
      exhibit a markedly increased prevalence of the metabolic syndrome, even when glucose
      tolerance is normal. For both maternal and future offspring, women with prior GDM need safe,
      efficient, and acceptable choices for contraceptive methods that do not enhance their already
      substantial risk to develop either overt diabetes or metabolic syndrome and associated
      sequelae. The intrauterine device (IUD) is a very effective and reversible contraceptive
      method without metabolic disturbances and therefore is an ideal contraceptive for women with
      prior GDM. Progestins do not increase globulin production; thus, they do not increase
      coagulation factors or blood pressure. A nonrandomized open-label prospective trial of
      healthy obese, reproductive-age women in California were studied about the metabolic effects
      of progestin-only long-acting reversible contraception levonorgestrel-releasing intrauterine
      system (LNG-IUS) and etonogestrel implant (ENG-I)] comparing with nonhormonal contraception
      (NHC). The changes in fasting glucose and insulin sensitivity were seen among obese at 3
      months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes mellitus</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of type-2 DM in women with history of gestational diabetes using implantable contraception.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>metabolic syndrome</measure>
    <time_frame>5 years</time_frame>
    <description>Prevalence of metabolic syndrome in women with history of gestational diabetes using implantable contraception.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>nonhormonal contraception</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nonhormonal intrauterine device tubal sterilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progestin implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jadelle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>progestin implant</intervention_name>
    <description>two small (2.5 mm Ã— 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix</description>
    <arm_group_label>progestin implant</arm_group_label>
    <other_name>Jadelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>nonhormonal contraception</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postpartum women with diagnosis of gestational diabetes mellitus

          -  Want to use implant contraception or nonhormonal contraceptions such as IUD or tubal
             sterilization

        Exclusion Criteria:

          -  Age less than 18 years old

          -  Diagnosis of diabetes mellitus at post partum period

          -  Cardiovascular disease, Liver disease, autoimmune disease

          -  The women that reject to continue in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manee Rattanachaiyanont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Manee Rattanachaiyanont</investigator_full_name>
    <investigator_title>Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital</investigator_title>
  </responsible_party>
  <keyword>GDM</keyword>
  <keyword>implant</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

